MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Puma Biotechnology Inc

Chiusa

SettoreSettore sanitario

3.4 -3.41

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.38

Massimo

3.52

Metriche Chiave

By Trading Economics

Entrata

-16M

3M

Vendite

-13M

46M

P/E

Media del settore

4.597

39.564

Margine di Profitto

6.464

Dipendenti

172

EBITDA

-14M

4M

Raccomandazioni

By TipRanks

Raccomandazioni

Vendi

Previsioni per 12 mesi

-14.77% downside

Dividendi

By Dow Jones

Utili prossimi

31 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

18M

178M

Apertura precedente

6.81

Chiusura precedente

3.4

Notizie sul Sentiment di mercato

By Acuity

16%

84%

29 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Puma Biotechnology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 lug 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

FCC Approves U.S. Cellular Sale to T-Mobile

11 lug 2025, 17:28 UTC

I principali Market Mover

SharpLink Gaming Gains on Ethereum Purchase

11 lug 2025, 16:57 UTC

Utili

BASF Cuts Outlook on Global Economy Uncertainty

11 lug 2025, 21:45 UTC

Discorsi di Mercato

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 lug 2025, 19:46 UTC

Acquisizioni, Fusioni, Takeovers

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 lug 2025, 19:45 UTC

Discorsi di Mercato

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 lug 2025, 19:05 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 lug 2025, 18:18 UTC

Discorsi di Mercato

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 lug 2025, 17:35 UTC

Discorsi di Mercato

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 lug 2025, 17:26 UTC

Discorsi di Mercato

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 lug 2025, 16:53 UTC

Discorsi di Mercato

Crude Futures Add to Early Gains -- Market Talk

11 lug 2025, 16:42 UTC

Utili

BASF Cuts Outlook on Global Economic Uncertainty

11 lug 2025, 16:08 UTC

Discorsi di Mercato

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 lug 2025, 16:05 UTC

Utili

BASF Will Publish Half-Year Results on July 30

11 lug 2025, 16:04 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

11 lug 2025, 16:04 UTC

Discorsi di Mercato

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 lug 2025, 16:03 UTC

Utili

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 lug 2025, 16:02 UTC

Utili

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 lug 2025, 16:01 UTC

Utili

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 lug 2025, 16:00 UTC

Utili

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 lug 2025, 15:59 UTC

Utili

BASF Cuts 2025 Earnings View

11 lug 2025, 15:58 UTC

Utili

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 lug 2025, 15:57 UTC

Utili

BASF 2Q EBIT Before Special Items EUR810M

11 lug 2025, 15:54 UTC

Utili

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 lug 2025, 15:54 UTC

Utili

BASF 2Q Sales Fell 2.1% on Year

11 lug 2025, 15:53 UTC

Utili

BASF 2Q Sales EUR15.77B

11 lug 2025, 15:52 UTC

Utili

BASF: This Was in Line With Consensus Estimates

11 lug 2025, 15:52 UTC

Utili

BASF 2Q Ebitda Before Special Items EUR1.77B

11 lug 2025, 15:49 UTC

Utili

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 lug 2025, 15:41 UTC

Discorsi di Mercato

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Confronto tra pari

Modifica del prezzo

Puma Biotechnology Inc Previsione

Obiettivo di Prezzo

By TipRanks

-14.77% in calo

Previsioni per 12 mesi

Media 3 USD  -14.77%

Alto 4 USD

Basso 2 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Puma Biotechnology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Vendi

2 ratings

0

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

3.07 / 3.075Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

29 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.